Kazuhiko Yonekura

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs · 1996 · 824 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 198 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models

Shuichi Ohkubo, Yasuo Kodama, Hiromi Muraoka et al. · Molecular Cancer Therapeutics · 2014 · 140 citations

Medicine, Medicinal Chemistry, Pharmacology +11

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations

Shinichi Hasako, Miki Terasaka, Naomi Abe et al. · Molecular Cancer Therapeutics · 2018 · 85 citations

Medicine, Oncology, Pharmacology +17

γ-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor

Yuji Basaki, Lumi Chikahisa, Kumio Aoyagi et al. · Angiogenesis · 2001 · 66 citations

Medicine, Pharmacology, Pharmacotherapy +11